piragrel sodium

Piragrel sodium (also known as pyragrel sodium) is a novel small molecule thromboxane A2 (TXA2) synthase inhibitor being developed by Hefei Institute of Pharmaceutical Industry and Guangzhou Boteng Biopharmaceutical Technology for the treatment of acute ischemic stroke and cerebral thrombosis. Chemically derived from a combination of ligustrazine and ferulic acid, piragrel sodium acts by inhibiting thromboxane synthase, thereby reducing the synthesis of thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. This mechanism of action provides antithrombotic and antiplatelet aggregation effects with a potentially lower risk of bleeding compared to traditional therapies like ozagrel. The drug is currently in Phase III clinical development in China as an intravenous injection.

Other names

piragrelpyragrelpyragrel sodiumsodium piragrelsodium pyragrel